QuidelOrtho (QDEL) - 2026 Q4 - Annual Results

Exhibit 99.1 QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results ― Delivered 6% Labs and 9% TRIAGE™ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25 ― ― Continued growth and margin expansion expected in FY26; free cash flow expected to improve by over $200 million ― February 11, 2026 SAN DIEGO, CA — QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for ...